Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical imiquimod 5% versus LEEP for high-grade cervical intraepithelial neoplasia
IRCT20230811059116N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Oct 2023
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Histological response rate and Regression rate compared with control group. Started Oct 2023; status: completed.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on IRCT20230811059116N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230811059116N1.